

Cigna Medical Coverage Policies – Musculoskeletal Implantable Intrathecal Drug Delivery Systems

Effective February 25, 2026



Instructions for use

The following coverage policy applies to health benefit plans administered by Cigna. Coverage policies are intended to provide guidance in interpreting certain standard Cigna benefit plans and are used by medical directors and other health care professionals in making medical necessity and other coverage determinations. Please note the terms of a customer's particular benefit plan document may differ significantly from the standard benefit plans upon which these coverage policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a coverage policy.

In the event of a conflict, a customer's benefit plan document always supersedes the information in the coverage policy. In the absence of federal or state coverage mandates, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of:

1. The terms of the applicable benefit plan document in effect on the date of service
2. Any applicable laws and regulations
3. Any relevant collateral source materials including coverage policies
4. The specific facts of the particular situation

Coverage policies relate exclusively to the administration of health benefit plans. Coverage policies are not recommendations for treatment and should never be used as treatment guidelines.

This evidence-based medical coverage policy has been developed by eviCore, Inc. Some information in this coverage policy may not apply to all benefit plans administered by Cigna.

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2025 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

©Copyright 2025 eviCore healthcare

CMM-210: Implantable Intrathecal Drug Delivery Systems

Definitions

General Guidelines

Indications

Replacement

Non-Indications

Codes (CMM-210)

References (CMM-210)

Definitions

- **Ashworth Scale (AS):** a tool classify the degree of spasticity and muscle tone. The following represents the clinical description of spasticity in the muscle being evaluated:
 - ◆ **0:** No increase in tone
 - ◆ **1:** Slight increase in tone giving a catch when the limb is moved in flexion or extension
 - ◆ **2:** More marked increase in muscle tone, but limb easily flexed
 - ◆ **3:** Considerable increase in tone, passive movement difficult
 - ◆ **4:** Limb rigid in flexion or extension
- **Modified Ashworth Scale (MAS):** a tool classify the degree of spasticity and muscle tone. The following represents the clinical description of spasticity in the muscle being evaluated:
 - ◆ **0:** No increase in tone
 - ◆ **1:** Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is(are) moved in flexion or extension
 - ◆ **1+:** Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM
 - ◆ **2:** More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved
 - ◆ **3:** Considerable increase in tone, passive movement difficult
 - ◆ **4:** Limb rigid in flexion or extension
- **Penn Spasm Frequency Score (PSFS):** a measure that assesses an individual's perception of spasticity frequency. The following represents the spasm frequency scoring:
 - ◆ **0:** No spasm
 - ◆ **1:** Mild spasms induced by stimulation
 - ◆ **2:** Infrequent full spasms less than once per hour
 - ◆ **3:** Spasms occurring more than once per hour
 - ◆ **4:** Spasms occurring more than 10 times per hour
- **Implantable Intrathecal Drug Delivery System** (pain pump or baclofen pump): a device used for the continuous infusion of a drug directly into the cerebrospinal fluid via a catheter placed in the intrathecal or epidural space. A pump is placed in the subcutaneous tissue of the abdomen and connected to the catheter. The pump reservoir holds the medication(s), and the pump is programmed to give a set dose of medication over time. For most individuals, it should be used as part of a program to facilitate restoration of function and return to activity, and not just for pain reduction. An intrathecal drug delivery trial can be accomplished by either a single intrathecal bolus injection or an intrathecal catheter infusion.

General Guidelines

Application of Guideline

- This guideline only applies to the use of an implantable intrathecal or epidural drug delivery system for **ANY** of the following conditions:
 - ◆ Non-malignant, chronic intractable pain (e.g., failed back surgery syndrome with low back pain and/or radicular pain, post-herpetic neuralgia, complex regional pain syndrome)
 - ◆ Severe, refractory spasticity or chronic intractable dystonia in individuals who are unresponsive to or cannot tolerate oral anti-spasticity agents (i.e., baclofen [Lioresal®])
 - ◆ Cancer-related pain
- This guideline does **NOT** apply to an implantable intrathecal or epidural drug delivery system for obstetrical or surgical epidural anesthesia use.
- The determination of medical necessity for the performance of an implantable intrathecal or epidural drug delivery system is always made on a case-by-case basis.

Injectates

- This guideline does **NOT** apply to an intrathecal or epidural drug delivery system for the following: Spinraza, chemotherapy, neurolytic substances, antispasmodics, antibiotics, antivirals, biologics (e.g., platelet rich plasma, stem cells, amniotic fluid, etc.), or any other injectates that are not in scope of management.

Indications

Non-Malignant, Chronic Intractable Pain

Trial

- A trial with a percutaneous intrathecal or epidural drug delivery system for non-malignant chronic intractable pain is considered **medically necessary** when **ALL** of the following criteria have been met:
 - ◆ There is documented pathology of non-malignant, chronic intractable pain (e.g., failed back surgery syndrome with low back pain and/or radicular pain, post-herpetic neuralgia, complex regional pain syndrome)
 - ◆ There has been a failure of a sufficient trial of at least six (6) months of provider-directed non-invasive pain management that includes **BOTH** of the following (unless there is a documented contraindication):
 - Active rehabilitative exercise
 - A fixed schedule dosing of opioids or other analgesics
 - ◆ Further surgical intervention or other treatment is not indicated or likely to be effective

- ◆ An attestation from a primary care physician, neurologist, physiatrist, psychiatrist, psychologist, or other licensed behavioral and/or medical health care provider (i.e., face-to-face or virtual assessment with or without psychological questionnaires and/or psychological testing) reveals no evidence of inadequately controlled mental and/or behavioral health conditions/issues (e.g., substance use disorders, depression, or psychosis) as a major contributor to chronic pain
- ◆ Individual agrees to a 50% reduction in systemic opioids prior to undergoing an intrathecal opioid trial

Permanent

- A permanent implantable intrathecal or epidural drug delivery system for non-malignant chronic intractable pain is considered **medically necessary** when **BOTH** of the following criteria have been met:
 - ◆ The above criteria for a trial of intrathecal or epidural opioid administration has been met
 - ◆ During an appropriate trial there is documentation of **BOTH** of the following:
 - There has been >50% reduction in pain for eight (8) hours
 - There has been a concomitant increase in function

Severe, Refractory Spasticity/Chronic Intractable Dystonia

Trial

- A trial with a percutaneous intrathecal drug delivery system for severe, refractory spasticity or chronic intractable dystonia is considered **medically necessary** for **EITHER** of the following clinical scenarios:
 - ◆ There is documentation that the individual is unresponsive, cannot tolerate, or has a contraindication to at least a six (6) week trial of **BOTH** of the following:
 - Oral antispasmodic drugs (i.e., baclofen [Lioresal®])
 - Physical therapy
 - ◆ Individual has **BOTH** of the following (as defined in **Definitions**):
 - A baseline average Ashworth score of at least 3 (or a Modified Ashworth score of 2)
 - A Spasm Frequency score of at least 2

Permanent

- A permanent implantable intrathecal or epidural drug delivery system for the treatment of severe, refractory spasticity or chronic intractable dystonia is considered **medically necessary** when **ALL** of the following criteria have been met:
 - ◆ The above criteria for a trial of intrathecal antispasmodic drug administration has been met
 - ◆ The trial resulted in a beneficial clinical response including, but not limited to, **EITHER** of the following:
 - At least a 2-point reduction in the Ashworth Score or Modified Ashworth Score for four (4) hours following an intrathecal trial bolus of baclofen
 - At least a 2-point reduction in the Spasm Frequency Score for four (4) hours following an intrathecal trial bolus of baclofen

Cancer-Related Pain

Trial

- A trial with a percutaneous intrathecal or epidural drug delivery system for cancer-related pain is considered **medically necessary** when there is failure, intolerance, or contraindication to non-invasive methods of pain control including systemic opioids.

Permanent

- A permanent implantable intrathecal or epidural drug delivery system for cancer-related pain is considered **medically necessary** if the individual has met the above criteria for a preliminary trial and has experienced at least a 50% reduction in pain during an appropriate trial.
 - ◆ **Criteria exception:** A trial with a percutaneous intrathecal or epidural drug delivery system for cancer-related pain is **not required** in the presence of advanced disease, when survival time is limited, and when the individual is considered high-risk for procedures.

Replacement

- Replacement of an implanted intrathecal or epidural drug infusion system is considered **medically necessary** for **ANY** of the following:
 - ◆ The existing device is documented to be nearing end of battery life
 - ◆ The existing device will no longer be functional and cannot be repaired
 - ◆ A built-in device component provides notification of impending failure

Non-Indications

Not Medically Necessary

- An implantable intrathecal or epidural drug delivery system (trial, permanent, or replacement) placed without meeting the criteria listed in the **Definitions**, the **General Guidelines**, and the **Indications** sections is considered **not medically necessary**.
- An intrathecal or epidural drug delivery system is considered **not medically necessary** for **ANY** other indication.
- Replacement of an implantable intrathecal infusion pump when the existing infusion pump and/or components remain functional is considered **not medically necessary**.

Codes (CMM-210)

The inclusion of any code in this table does not imply that the code is under management or requires prior authorization. Refer to the applicable health plan for management details. Prior authorization of a code listed in this table is not a guarantee of payment. The Certificate of Coverage or Evidence of Coverage policy outlines the terms and conditions of the member's health insurance policy.

CPT®	Code Description/Definition
62320	Injection(s), of diagnostic or therapeutic substance(s) (e.g., anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, cervical or thoracic; without imaging guidance.
62321	Injection(s), of diagnostic or therapeutic substance(s) (e.g., anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, cervical or thoracic; with imaging guidance (i.e., fluoroscopy or CT)
62322	Injection(s), of diagnostic or therapeutic substance(s) (e.g., anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); without imaging guidance.
62323	Injection(s), of diagnostic or therapeutic substance(s) (e.g., anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); with imaging guidance (i.e., fluoroscopy or CT)
62324	Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (e.g., anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, cervical or thoracic; without imaging guidance.
62325	Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (e.g., anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, cervical or thoracic; with imaging guidance (i.e., fluoroscopy or CT)
62326	Injection (s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (e.g., anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); without imaging guidance.
62327	Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (e.g., anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); with imaging guidance (i.e., fluoroscopy or CT)
62350	Implantation, revision or repositioning of tunneled intrathecal or epidural catheter, for long-term medication administration via an external pump or implantable reservoir/infusion pump; without laminectomy
62351	Implantation, revision or repositioning of tunneled intrathecal or epidural catheter, for long-term medication administration via an external pump or implantable reservoir/infusion pump; with laminectomy
62360	Implantation or replacement of device for intrathecal or epidural drug infusion; subcutaneous reservoir
62361	Implantation or replacement of device for intrathecal or epidural drug infusion; nonprogrammable pump
62362	Implantation or replacement of device for intrathecal or epidural drug infusion; programmable pump, including preparation of pump with or without programming

References (CMM-210)

1. Ackerman L, Follett K, Rosenquist R. Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations. *J Pain Symptom Manage*. 2003;26(1):668-677.
2. American College of Occupational and Environmental Medicine. *Occupational Medicine Practice Guideline*. 2nd ed. 2008.
3. American Medical Association. *Current Procedural Terminology – 2014 Professional Edition*.
4. Anderson V, Burchiel K. A prospective study of long term intrathecal morphine in the management of chronic nonmalignant pain. *Neurosurgery*. 1999;44:289-300.
5. Anderson V, Cooke B, Burchiel K. Intrathecal hydromorphone for chronic nonmalignant pain: a retrospective study. *Pain Med*. 2001;2(4):287-297.
6. Angel I, Gould H Jr, Carey M. Intrathecal morphine pump as a treatment option in chronic pain of nonmalignant origin. *Surg Neurol*. 1998;49(1):92-98.
7. Ashworth Scale/Modified Ashworth Scale. Shirley Ryan Ability Lab. Last updated 2016 May 26. <https://www.sralab.org/rehabilitation-measures/ashworth-scale-modified-ashworth-scale>.
8. Boswell M, Shah R, Everett C, et al. Interventional Techniques: Evidence-based Practice Guidelines in The Management of Chronic Spinal Pain: Evidence-Based Practice Guidelines. *Pain Physician*. 2005;8:1-47.
9. Brown J, Klapow J, Doleys D, et al. Disease-specific and generic health outcomes: a model for the evaluation of long-term intrathecal opioid therapy in noncancer low back pain patients. *Clin J Pain*. 1999;15:122-131.
10. Bottros M, Christo P. Current perspectives on intrathecal drug delivery. *J Pain Res*. 2014;7:615–626.
11. Dahm P, Nitescu P, Appelgren L, Curelaru I. Efficacy and technical complications of long-term continuous intraspinal infusions of opioid and/or bupivacaine in refractory nonmalignant pain: a comparison between the epidural and the intrathecal approach with externalized or implanted catheters and infusion pumps. *Clin J Pain*. 1998;14:4-16.
12. Dario A, Scamoni C, Picano M, et al. The infection risk of intrathecal drug infusion pumps after multiple refill procedures. *Neuromodulation*. 2005;8(1):36-39.
13. Deer T. Current and future trends in spinal cord stimulation for chronic pain. *Curr Pain Headache Rep*. 2001;5(6):503-509.
14. Deer T, Chapple I, Classen A, et al. Intrathecal drug delivery for treatment of chronic low back pain: report from the National Outcomes Registry for Low Back Pain. *Pain Med*. 2004;5(1):6-13.
15. Deer T, Krames ES, Hassenbusch SJ, Burton A, Caraway D, Dupen S, et al. Polyanalgesic consensus conference 2007: Recommendations for the management of pain by intrathecal (intraspinal) drug delivery: Report of an interdisciplinary expert panel. *Neuromodulation*. 2007;10(4):300-328.
16. Deer TR, Hayek SM, Pope JE, et al. The polyanalgesic consensus conference (PACC): recommendations for training of intrathecal drug delivery infusion therapy. *Neuromodulation*. 2017;20(2):133-154. doi:10.1111/ner.12543.
17. Deer TR, Kim C, Bowman R, Tolentino D, Stewart C, Tolentino W. Intrathecal ziconotide and opioid combination therapy for noncancer pain: an observational study. *Pain Physician*. 2009;12(4):E291-E296.
18. Deer TR, Smith HS, Burton AW, et al. Comprehensive Consensus Based Guidelines on Intrathecal Drug Delivery Systems in the Treatment of Pain Caused by Cancer Pain. *Pain Physician*. 2011;14:E283-E312.
19. Deer TR, Pope JE, Hayek SM, et al. The polyanalgesic consensus conference (PACC): recommendations on intrathecal drug infusion systems best practices and guidelines. *Neuromodulation*. 2017;20(2):96-132.

20. Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intrad spinal) drug delivery: report of an interdisciplinary expert panel. *Neuromodulation*. 2012;15(5):436-464. doi:10.1111/j.1525-1403.2012.00476.x.
21. Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference--2012: recommendations on trialing for intrathecal (intrad spinal) drug delivery: report of an interdisciplinary expert panel. *Neuromodulation*. 2012;15(5):420-35. doi:10.1111/j.1525-1403.2012.00450.x.
22. Deer TR, Smith HS, Burton AW, et al. Center For Pain Relief, Inc. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. *Pain Physician*. 2011;14(3):E283-E312.
23. Du Pen S, Du Pen A, Hillyer J. Intrathecal hydromorphone for intractable nonmalignant pain: a retrospective study. *Pain Med*. 2006;7(1):10-15.
24. FDA News Release. FDA alerts doctors, patients about risk of complications when certain implanted pumps are used to deliver pain medications not approved for use with the devices. 2018 Nov 14. <https://www.fda.gov/news-events/press-announcements/fda-alerts-doctors-patients-about-risk-complications-when-certain-implanted-pumps-are-used-deliver>.
25. Grider JS, Harned ME, Etscheidt MA. Patient selection and outcomes using a low-dose intrathecal opioid trialing method for chronic nonmalignant pain. *Pain Physician*. 2011;14(4):343-351.
26. Guillaume D, Van Haverbergh A, Vloeberghs M, et al. A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity. *Arch Phys Med Rehabil*. 2005;86:2165-2171.
27. Hamza M, Doleys DM, Saleh IA, Medvedovsky A, Verdolin MH, Hamza M. A Prospective, Randomized, Single-Blinded, Head-to-Head Long-Term Outcome Study, Comparing Intrathecal (IT) Boluses With Continuous Infusion Trialing Techniques Prior to Implantation of Drug Delivery Systems (DDS) for the Treatment of Severe Intractable Chronic Nonmalignant Pain. *Neuromodulation*. 2015;18(7):636-48.
28. Hamza M, Doleys D, Wells M, et al. Prospective study of 3-year follow-up of low-dose intrathecal opioids in the management of chronic nonmalignant pain. *Pain Med*. 2012;13(10):1304-1313. doi:10.1111/j.1526-4637.2012.01451.x.
29. Hassenbusch S, Portenoy R, Cousins M, et al. Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery--report of an expert panel. *J Pain Symptom Manage*. 2004;27(6):540-563.
30. Krames E. Intrad spinal opioid therapy for chronic nonmalignant pain: current practice and clinical guidelines. *J Pain Symptom Manage*. 1996;11(6):333-352.
31. Kumar K, Hunter G, Demeria D. Treatment of chronic pain by using intrathecal drug therapy compared with conventional pain therapies: a cost-effectiveness analysis. *J Neurosurg*. 2002;97(4):803-810.
32. Miele V, Price K, Bloomfield S, et al. A review of intrathecal morphine therapy related granulomas. *Eur J Pain*. 2006;10(3):251-261.
33. Manchikanti L, Abdi S, Atluri S, et al. An update of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. Part II: guidance and recommendations. *Pain Physician*. 2013;16(2 Suppl):S49-S283.
34. Manchikanti L, Falco FJ, Singh V, et al. An update of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. Part I: introduction and general considerations. *Pain Physician*. 2013;16(2 Suppl):S1-S48.
35. McIntyre A, Mays R, Mehta S, et al. Examining the effectiveness of Intrathecal baclofen on spasticity in individuals with chronic spinal cord injury: a systemic review. *J Spinal Cord Med*. 2014;37(1):11-18.
36. Modified Ashworth scale and spasm frequency score in spinal cord injury: reliability and correlation. *Spinal Cord*. 2016;54:702-708
37. North American Spine Society (NASS). *NASS Coverage Policy Recommendations: Intrathecal*

Drug Delivery Systems. Burr Ridge, IL: North American Spine Society. March 2017.

38. Nguyen H, Garber J, Hassenbusch S. Spinal analgesics. *Anesth Clin of NA*. 2003;21(4).
39. Osenbach R, Harvey S. Neuraxial infusion in patients with chronic intractable cancer and noncancer pain. *Curr Pain Headache Rep*. 2001;5(3):241-249.
40. Penn RD et al. Intrathecal baclofen for severe spinal spasticity. *N Engl J Med*. 1989;320:1517-1521.
41. Penn Spasm Frequency Scale. Shirley Ryan Ability Lab. Last updated 2013 Jan 04. <https://www.sralab.org/rehabilitation-measures/penn-spasm-frequency-scale>.
42. Raffaeli W, Marconi G, Fanelli G, et al. Opioid-related side-effects after intrathecal morphine: a prospective, randomized, double-blind dose-response study. *Eur J Anaesthesiology*. 2006;23:605-610.
43. Rauck R, Wallace M, Leong M, et al; Ziconotide 301 Study Group. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. *J Pain Symptom Manage*. 2006;31(5):393-406.
44. Staal C, Arends A, Ho S.A self-report of quality of life of patients receiving intrathecal baclofen therapy. *Rehabil Nurs*. 2003;28(5):159-163.
45. Thimineur M, Kravitz E, Vodapally M. Intrathecal opioid treatment for chronic non-malignant pain: a 3-year prospective study. *Pain*. 2004;109(3):242-249.
46. Turner J, Sears J, Loeser J. Programmable intrathecal opioid delivery systems for chronic noncancer pain: a systematic review of effectiveness and complications. *Clin J Pain*. 2007;23(2):180-195.
47. van Hilten B, van de Beek W, Hoff J, et al. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. *N Engl J Med*. 2000;343(9):625-630.
48. Waara-Wolleat K, Hildebrand K, Stewart G. A review of intrathecal fentanyl and sufentanil for the treatment of chronic pain. *Pain Med*. 2006;7:251-259.
49. Winkelmuller M, Winkelmuller W. Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. *J Neurosurg*. 1996;85:458-467.
50. Yoshida G, Nelson R, Capen D, Nagelberg et al. Evaluation of continuous intraspinal narcotic analgesia for chronic pain from benign causes. *Am J Orthop*. 1996;25(10):693-694.